India to Switzerland: Acarbose Export Trade Route

To import Acarbose formulations into Switzerland, the product must obtain marketing authorization from Swissmedic. The application should be structured in the Common Technical Document (CTD) or electronic CTD (eCTD) format, encompassing modules on administrative information, quality, non-clinical, and clinical data. While specific approval timelines and fees are not publicly detailed, applicants should anticipate a comprehensive review process.

Swissmedic mandates that foreign manufacturing facilities comply with GMP standards equivalent to those in Switzerland. For manufacturers in countries without a recognized GMP control system, such as India, Swissmedic requires evidence of GMP compliance through inspection reports or audit reports. These documents must be current, typically not older than three years, and should confirm that the manufacturing site adheres to GMP standards. Swissmedic reserves the right to conduct its own inspections if deemed necessary.

Indian manufacturers exporting Acarbose formulations to Switzerland must demonstrate GMP compliance. Since India is not listed among countries with a recognized GMP control system by Swissmedic, Indian manufacturers must provide up-to-date GMP certificates or inspection reports from competent authorities. These documents should confirm adherence to GMP standards and be no older than three years.

As of March 2026, specific details regarding Swissmedic's inspections or regulatory actions against Indian pharmaceutical companies are not publicly available. However, Swissmedic has intensified controls on international trade with suppliers from non-EU countries, including India, to prevent falsified medicinal products from entering the supply chain. In a campaign, Swissmedic examined 16 companies with the "Import for export" license module, revealing deficiencies in documentation and supply chain traceability. This underscores the importance of maintaining rigorous quality standards and thorough documentation for Indian exporters.

Between 2024 and 2026, Swissmedic has implemented several regulatory changes affecting pharmaceutical imports:

• September 2025: Swissmedic revised the guidance document on formal requirements, clarifying submission formats and modifying requirements for information for healthcare professionals and package leaflets associated with export licenses for veterinary medicinal products.

• November 2025: Swissmedic intensified controls on international trade with suppliers from non-EU countries, including India, to prevent falsified medicinal products from entering the supply chain. A targeted campaign uncovered deficiencies in documentation and supply chain traceability among companies importing medicinal products from non-EU countries.

These developments highlight Swissmedic's commitment to ensuring the safety and quality of medicinal products entering Switzerland. Indian exporters must stay informed about these regulatory changes and ensure full compliance to facilitate successful importation of Acarbose formulations into the Swiss market.

In 2024, the Swiss market for alpha-glucosidase inhibitors, including Acarbose formulations, experienced a 20.97% growth compared to the previous year. This surge is primarily driven by the increasing prevalence of type 2 diabetes, an aging population, and substantial healthcare expenditure. Switzerland's universal health coverage ensures broad access to diabetes treatments, further fueling demand. While specific data on domestic production versus imports of Acarbose formulations is limited, the country's robust pharmaceutical industry suggests a combination of both.

Switzerland imposes a 0% MFN import duty on pharmaceutical products classified under HS code 30049099, encompassing finished Acarbose formulations. However, an import VAT of 8.1% is levied on the total value of the goods, including ancillary costs up to the Swiss destination, such as transport and insurance. Switzerland's FTAs with various countries may offer preferential rates or exemptions for pharmaceutical imports, potentially impacting the overall cost structure.

India's exports of finished Acarbose formulations to Switzerland represent a minor fraction of the market, accounting for 0.2% of India's total Acarbose formulation exports, valued at $6.8 million. The primary exporters from India include DERRIC WOOD and GNH INDIA PHARMACEUTICALS LIMITED, with the main Swiss importer being TRANS SPED AG - SMI. Other major suppliers of Acarbose formulations to Switzerland likely include European Union manufacturers and potentially China, given their significant pharmaceutical production capacities. While specific pricing data is not readily available, India's competitive manufacturing costs often result in more affordable pharmaceutical products compared to European counterparts.

India is a global leader in generic pharmaceutical production, accounting for approximately 20% of the global supply by volume as of 2025. The country's extensive manufacturing infrastructure includes over 1,300 facilities registered with the U.S. FDA for the fiscal year 2024, with 134 dedicated to finished dosage forms (FDFs). This robust capacity enables the efficient production of Acarbose formulations, such as tablets and capsules, at competitive costs. Additionally, numerous Indian manufacturers hold WHO-GMP certifications, ensuring adherence to international quality standards. For instance, companies like Granules India have expanded their finished dosage capabilities, with their Genome Valley site receiving U.S. FDA approval in August 2025, adding an additional 10 billion doses of formulation capacity.

India's Acarbose formulations are competitively priced compared to those from China and the European Union. While specific pricing data for Acarbose is limited, trends in similar pharmaceutical products indicate that Indian manufacturers offer cost advantages due to economies of scale and lower production costs. Quality perception is high, with Indian facilities frequently obtaining approvals from stringent regulatory bodies such as the U.S. FDA and the European Medicines Agency. For example, Akums Drugs and Pharmaceuticals' units in Haridwar received European GMP certification in 2024. In contrast, Chinese manufacturers have faced challenges in meeting certain international quality standards, and EU manufacturers often have higher production costs, leading to more expensive formulations. Swiss regulatory authorities, including Swissmedic, recognize and accept Indian pharmaceutical products that meet international standards, ensuring their suitability for the Swiss market.

The India-Switzerland supply chain for Acarbose formulations has demonstrated reliability, supported by India's substantial manufacturing capacity and adherence to international quality standards. Indian manufacturers have invested in state-of-the-art facilities with advanced packaging and cold chain capabilities to ensure product integrity during transit. For instance, Granules India's Genome Valley facility, approved by the U.S. FDA in August 2025, added significant capacity for finished dosage forms. While there have been occasional regulatory observations, such as the U.S. FDA's Form 483 issued to Dr. Reddy's Laboratories in May 2024, these were promptly addressed, with the facility achieving a Voluntary Action Indicated (VAI) status by August 2024. Overall, Indian manufacturers maintain a strong compliance track record, and ongoing investments suggest a commitment to expanding capacity and ensuring consistent supply.

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a steady supply of Acarbose formulations.

• Negotiate Favorable Minimum Order Quantities (MOQs): While MOQs can vary, collaborating closely with suppliers can help establish quantities that align with your demand forecasts and storage capabilities.

• Establish Clear Payment Terms: Common payment terms in India-Switzerland pharmaceutical trade include letters of credit (LC) and advance payments. Clearly define terms to ensure mutual understanding and compliance.

• Conduct Thorough Supplier Qualification: Evaluate potential suppliers based on their regulatory approvals (e.g., U.S. FDA, WHO-GMP), production capacity, quality control measures, and track record in international markets.

• Monitor Regulatory Compliance: Regularly review suppliers' compliance with international standards and any recent regulatory inspections to ensure ongoing adherence to quality and safety requirements.

1. Swissmedic Registration Verification: Confirm that the Acarbose formulation is registered with Swissmedic, the Swiss Agency for Therapeutic Products. This ensures the product is authorized for sale within Switzerland.

2. Good Manufacturing Practice (GMP) Certification: Obtain a valid GMP certificate from the Indian manufacturer. Swissmedic recognizes GMP standards equivalent to those of the Pharmaceutical Inspection Co-operation Scheme (PIC/S).

3. Drug Master File (DMF) Assessment: Review the DMF submitted by the manufacturer, ensuring it contains comprehensive information on the manufacturing process, controls, and stability data of the Acarbose formulation.

4. Quality Management System Evaluation: Assess the manufacturer's quality management system to ensure it aligns with international standards, including ISO 9001 and ISO 13485, which are pertinent to pharmaceutical manufacturing.

5. Regulatory Compliance Check: Verify that the manufacturer complies with the regulations set forth by the Central Drugs Standard Control Organisation (CDSCO) in India, including adherence to the Drugs and Cosmetics Act and Rules.

6. Supply Chain Transparency: Ensure the manufacturer provides a clear and documented supply chain for raw materials used in the Acarbose formulation, demonstrating traceability and quality control.

7. Pharmacovigilance System Review: Confirm that the manufacturer has an effective pharmacovigilance system in place to monitor and report adverse drug reactions, ensuring ongoing product safety.

8. Previous Audit Reports Examination: Request and review any previous audit reports from regulatory authorities or third-party auditors to assess the manufacturer's compliance history.

9. Product Recall History Analysis: Investigate any history of product recalls associated with the manufacturer to identify potential quality or compliance issues.

10. Financial Stability Assessment: Evaluate the financial stability of the manufacturer to ensure they can maintain consistent production and supply of the Acarbose formulation.

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for each batch, confirming the product meets specified quality standards.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for customs and regulatory purposes.

3. GMP Certificate: Issued by the relevant regulatory authority, confirming the manufacturing facility complies with GMP standards.

4. Stability Data: Includes studies conducted under International Council for Harmonisation (ICH) guidelines, demonstrating the product's shelf life and stability under various conditions.

5. Batch Manufacturing Records: Detailed documentation of the manufacturing process for each batch, ensuring consistency and traceability.

6. Drug Master File (DMF): Comprehensive document detailing the manufacturing process, controls, and other pertinent information about the drug product.

7. Free Sale Certificate: Issued by the CDSCO, indicating that the product is freely sold in India and complies with local regulations.

8. Insurance Certificates: Proof of liability insurance coverage, ensuring protection against potential claims related to product quality or safety.

9. Environmental Monitoring Reports: Documentation of the manufacturing facility's environmental controls, ensuring compliance with hygiene and contamination standards.

10. Analytical Method Validation Reports: Evidence that the analytical methods used for testing the product are suitable and reliable.

1. Regulatory Non-Compliance: Recent warning letters or sanctions from regulatory bodies such as the FDA or WHO indicate serious compliance issues.

2. GMP Certification Suspension: Suspension or revocation of GMP certification suggests significant lapses in manufacturing practices.

3. Unrealistically Low Pricing: Prices significantly below market rates may indicate cost-cutting measures that compromise product quality.

4. Lack of Stability Data: Inability to provide comprehensive stability data raises concerns about the product's shelf life and efficacy.

5. Limited Export Experience: No history of exporting to European markets may suggest unfamiliarity with stringent EU regulatory requirements.

6. Resistance to Audits: Hesitation or refusal to allow facility audits indicates potential issues with transparency and compliance.

7. Frequent Product Recalls: A history of product recalls points to recurring quality control problems.

8. Inconsistent Documentation: Discrepancies or incomplete information in provided documents suggest poor record-keeping or attempts to conceal issues.

9. Negative Industry Reputation: Reports of unethical practices or poor product quality from industry sources are cause for concern.

10. High Staff Turnover: Frequent changes in key personnel may indicate internal instability affecting product quality.

By adhering to these guidelines, Swiss companies can effectively qualify Indian suppliers of Acarbose formulations, ensuring compliance with regulatory standards and the delivery of high-quality pharmaceutical products.